SCHEMBL6851683

SCHEMBL6851683

Cc1noc(C)c1SNc1ccc(Cl)cc1C(=O)Nc1ccc(S(=O)(=O)N2CC(C)OC(C)C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
POLB P06746 2/20 0.47
THRB P10828 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 2/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
USP2 O75604 2/20 0.46
GAA P10253 2/20 0.46
ALDH1A1 P00352 4/20 0.45
HTT P42858 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
DDIT3 P35638 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491714 0.85 THRB (0.51) MAPTNPSR1POLBTHRBMEN1
SCHEMBL491717 0.85 THRB (0.51) MAPTNPSR1POLBTHRBMEN1
SCHEMBL972763 0.84 THRB (0.51) MAPTNPSR1POLBTHRBMEN1
SCHEMBL972764 0.84 THRB (0.51) MAPTNPSR1POLBTHRBMEN1
SCHEMBL491990 0.79 THRB (0.59) MAPTNPSR1POLBTHRBMEN1
SCHEMBL491991 0.79 THRB (0.59) MAPTNPSR1POLBTHRBMEN1
SCHEMBL491819 0.77 MAPT (0.44) MAPTNPSR1POLBTHRBMEN1
SCHEMBL491976 0.74 THRB (0.59) MAPTNPSR1POLBTHRBMEN1
SCHEMBL491977 0.74 THRB (0.59) MAPTNPSR1POLBTHRBMEN1
SCHEMBL492080 0.72 KMT2A (0.60) MAPTNPSR1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161099-A1 USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-29 WO disclosed
WO-2011147810-A1 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-01 WO disclosed
WO-2011095553-A1 SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-11 WO disclosed
WO-2011095534-A1 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-11 WO disclosed
WO-2010081647-A2 SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 WO disclosed